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Intraocular pressure rise is predictive of vision
improvement after intravitreal triamcinolone
acetonide for diabetic macular oedema:
a retrospective analysis of data from a
randomised controlled trial
Roderick F O’Day1*, Daniel Barthelmes1, Meidong Zhu1, Tien Y Wong2,3, Ian L McAllister4, Jennifer J Arnold5
and Mark C Gillies1
Abstract
Background: Intravitreal triamcinolone acetonide (IVTA) is an effective treatment for recalcitrant diabetic macular
oedema (DMO). It has been shown to improve vision with benefits persisting up to five years. The most common
initial side effect of IVTA treatment is rise in intraocular pressure, occurring in approximately 50% of patients within
the first 6 months of treatment. We evaluated whether there is a correlation between the development of intraocular
pressure rise and improvement in vision.
Methods: Analysis of individual data from 33 eyes of 33 participants treated with IVTA for DMO from a prospective,
randomised, double-masked, placebo controlled trial. The degree of intraocular pressure (IOP) rise was correlated with
improvement in best-corrected visual acuity (BCVA) at 1 and 6 months.
Results: The proportion of eyes gaining 5 or more logMAR letters was higher in eyes with greater IOP rise (p = 0.044).
Better absolute improvement in BCVA at 6 months (p = 0.045) was also found in eyes with greater IOP rise. Regression
analyses revealed a correlation between IOP rise of 10 or more mmHg and absolute BCVA improvement at 6 months
(odds ratio 1.22, 95% confidence interval 1.01-1.48, p = 0.039), but not at 1 month.
Conclusions: IOP rise and vision improvement appear to be correlated following IVTA for DMO, suggesting that
the mechanisms that cause both may be linked.
Trial Registration: Clinical trials.gov NCT00167518, September 5, 2005.
Keywords: Intravitreal triamcinolone, Diabetic macular oedema, Vision improvement, Intraocular pressure rise,
Adverse events, Efficacy
Background
The treatment of diabetic macular oedema (DMO), the
commonest cause of vision loss in people with diabetes,
is rapidly evolving [1]. The past ten years have seen a
progressive shift away from laser photocoagulation ther-
apy with the emergence of new pharmacotherapeutic
approaches. Much of the recent focus has been on intra-
vitreal inhibitors of vascular endothelial growth factor
(VEGF). These are rapidly becoming the standard of
care for diffuse DMO [2]. VEGF inhibitors are generally
well tolerated, however, potentially significant systemic
and ocular side effects have not been comprehensively
excluded [3,4]. In particular, it has been suggested that
VEGF may play a neuroprotective role, the inhibition of
which may lead to loss of vision in the long-term [5].
Intravitreal triamcinolone (IVTA) is another proven treat-
ment for recalcitrant DMO with well-known side-effects
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[6-12]. In patients with persistent DMO despite laser treat-
ment, intravitreal injections of triamcinolone acetonide
were shown to improve vision and reduce macular thick-
ness with benefits persisting up to five years [6-8]. In that
study, IVTA treatment doubled the chance of visual acuity
improvement and halved the chance of deterioration in eyes
with advanced DMO [6-8].
The ocular safety of IVTA treatment has been thor-
oughly explored [6-8,13-16]. The most common adverse
events of IVTA treatment are intraocular pressure (IOP)
rise and accelerated cataract formation, particularly pos-
terior subcapsular cataract. Reported rates of IOP rise
differ; in our study approximately 50% of eyes had an
IOP rise of 5 or more mmHg within the first six months
of IVTA treatment [6-8]. IOP rise has been shown to be
significantly associated with cataract progression, sug-
gesting that these steroid-related adverse events may
have similar aetiologies, for example genetic polymor-
phisms in the steroid receptor [15]. In this study, we
analysed whether IOP rise was linked with visual acuity
improvement using data from the Triamcinolone for
Diabetic Macular Oedema (TDMO) study [6-8]. If so,
this would suggest that the mechanisms of IOP rise and
vision improvement after IVTA for DMO are similar
and may help to further advance our understanding of
how IVTA acts on macular oedema.
Methods
This analysis is based on data from the TDMO study,
which was the first major prospective, randomised,
double masked, placebo-controlled clinical trial to test
the hypothesis that IVTA safely improves visual acuity
in eyes with advanced DMO over 2 years [6-8]. For the
TDMO study, patients were recruited from a major ter-
tiary referral centre. Inclusion criteria were persistent
diabetic macular oedema involving the central fovea per-
sisting three months or more after adequate laser treat-
ment and best corrected visual acuity (BCVA) in the
affected eye of 6/9 or worse [6-8]. A total of 69 eyes
were enrolled in the study, 4 of which were lost to follow
up within the first three months. Of the remaining 65
eyes, 33 received triamcinolone treatment and are the
subject of the present analysis. At baseline eyes received
either a 4 mg IVTA injection – 0.1 ml of Kenacort 40
(40 mg/ml triamcinolone acetonide; Bristol-Myers Squibb,
Noble Park, Australia) – or a sham-injection with sub-
conjunctival saline. The TDMO study was conducted in
accordance with the Declaration of Helsinki and was
approved by the South Eastern Sydney Area Health Service
and University of Sydney research ethics committees.
Written informed consent was obtained from all patients
prior to treatment assignment.
For the purpose of this analysis, the visual acuity out-
comes were (A) change in number of letters read on a
Logarithm of the Minimal Angle of Resolution (LogMAR)
chart and (B) proportion of eyes that had improved vision
by 5 or more LogMAR letters. Both were assessed as differ-
ence between baseline and 1 or 6 months. During this time
all eyes received a single injection of IVTA. Change in IOP
was defined as the difference between baseline and the
highest IOP measured within 6 months after IVTA treat-
ment. IOP was measured using Goldmann applanation
tonometry. Various definitions of IOP rise are used in the
literature including, absolute values [17,18] percentage
increase from baseline [19], and change from baseline
[13-19]. No one definition has been universally adopted.
For a descriptive analysis, we stratified eyes into three
groups according to degree of change in IOP – less than a
5 mmHg increase, increase by 5 mmHg or more but less
than 10 mmHg and increase by 10 mmHg or more – from
baseline. Intraocular pressure and VA data at 1 and
6 months were compared to baseline. This enabled us to
stratify our analyses to effectively assess eyes that have a
moderate intraocular pressure response, i.e. those gaining 5
or more, but less than 10 mmHg, and those that have a
strong intraocular pressure response, i.e. those gaining 10
or more mmHg. For the regression analysis, eyes were allo-
cated to two groups: less than 10 mmHg in increase and
10 mmHg or more increase.
Statistical analysis
Data are presented as mean ± standard deviation (SD)
when normally distributed or as median and [interquartile
range] if not. Normality was assessed using the Shapiro-
Wilks test. The homogeneity of variances between two
groups was assessed using Levene’s test. Differences in
continuous variables between multiple groups were com-
pared using a one-way ANOVA or the Kruskal-Wallis for
normally and not normally distributed data, respectively.
In cases of significant ANOVA results, post-hoc testing
was performed. If equal variances could be assumed, a
Bonferroni correction was applied. If not, Dunn’s test was
applied. Differences in proportions between three groups
were analysed using Fisher’s exact test with the Freeman-
Halton extension. Correcting for baseline characteristics,
two separate binary logistic regression models were per-
formed to examine whether improvement in vision at 1
(model A) and 6 months (model B) was predictive of IOP
increase. Eyes with missing values were excluded from
these analyses. The dependent variable was IOP rise within
six months of IVTA injection. The independent variables
were change in BCVA (continuous variable) at 1 or
6 months, age at baseline (continuous variable), gender
(binary variable) and phakic status at baseline (binary vari-
able). Collinearity was examined by calculating tolerance
and variance inflation factor (VIF).
A priori a p value of <0.05 was defined as statistically
significant. All data were analysed using a commercially
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available software package (PASW 21, SPSS Inc., Chicago,
IL, USA).
Results
Of the 33 eyes treated with IVTA in the TDMO study,
6 (18%) were pseudophakic at baseline and 15 (45%)
were female. The mean age of patients at baseline was
63.27 ± 10.10 years and median glycosylated haemoglo-
bin (HbA1c) was 7.7 [5.7 to 9.5] percent. The mean
central macular thickness (CMT) was 444 ± 125 micro-
metres, IOP was 16.55 ± 2.56 mmHg and median BCVA
was 64.0 [52.5 to 70.0] letters logMar.
Table 1 shows the baseline characteristics of eyes
treated with IVTA stratified with respect to intraocular
pressure response. There was no significant difference in
the measured baseline characteristics – age, gender,
HbA1c, phakic status, IOP, BCVA and CMT – between
the groups classified according to degree of IOP rise.
Data on IOP rise was available for all eyes. BCVA data
was not available for 4 eyes at the 6 month follow-up,
but was otherwise complete.
IOP rise and visual outcomes
Seventeen eyes (52%) had an IOP change from baseline
of less than a 5 mmHg or more increase, 8 (24%) had a
rise of 5 or more but less than 10 mmHg and 8 (24%)
had a rise of 10 or more mmHg. Eyes that had greater
IOP rise had significantly greater chance of having an
improvement in vision by 5 or more letters at 1 month
(p = 0.044, Table 2) and there was a trend for these eyes to
have better absolute improvement in BCVA (p = 0.058,
Table 2). At 6 months, eyes that exhibited greater IOP rise
had better absolute improvement in BCVA (p = 0.045,
Table 2), but the proportion of eyes improving by 5 of
more letters was not significant (Table 2).
Regression analyses revealed a correlation between
IOP rise of 10 or more mmHg and absolute vision im-
provement at 6 months (odds ratio 1.22, 95% confidence
interval 1.01-1.48, p = 0.039, Table 3), but not at 1 month.
Baseline age, gender and phakic status did not predict
IOP rise by 10 or more mmHg (Table 3).
Discussion
This analysis examined the relationship between the de-
velopment of adverse events and visual outcomes after
IVTA treatment in order to gain further insights into its
mechanism of action in treating DMO. We found a cor-
relation between IOP rise and vision improvement at
two time points in the first 6 months after a single treat-
ment with IVTA for DMO. It seems that the greater the
IOP rise, the more likely eyes are to improve in vision,
at least in the short term.
Significant research has examined the clinical applica-
tion of glucocorticoids in inflammatory and oedematous
diseases of the eye, however, the mechanisms of steroid-
induced changes are yet to be fully elucidated. Steroid-
induced IOP rise is thought to be due to activation of
glucocorticoid receptors in the trabecular meshwork
[20,21]. It has been suggested that polymorphisms of the
Myocilin gene, which is upregulated by glucocorticoids,
may be responsible for steroid-induced IOP rise [22]. Ul-
timately, steroids cause biochemical and ultrastructural
changes to the trabecular meshwork resulting in greater
resistance in the aqueous humour outflow tract [23,24].
Less is known about the mechanism of vision improve-
ment by IVTA than that of IOP rise. It is likely to be more
complex than reduction in macular thickness alone, as evi-
denced by a lack of a correlation between these two clinical
outcomes [25]. It has been proposed that improvement in
glial and neuronal function may explain the improvement
in vision following IVTA treatment [26-28]. This is consist-
ent with recent clinical findings that there is a strong link
between photoreceptor integrity and visual acuity out-
comes in patients treated with IVTA for DMO [29].
A strong correlation between IOP rise and cataract for-
mation has previously been shown, suggesting a common
Table 1 Baseline characteristics of 33 eyes treated with IVTA stratified with respect of change in IOP from baseline
Characteristic
IOP change < 5 mmHg rise IOP rise 5–9 mmHg IOP rise ≥ 10 mmHg
P value
(n = 17) (n = 8) (n = 8)
Age (y) 63.8 ± 8.4 63.9 ± 15.7 61.5 ± 7.2 0.864
Gender, female (n) 9 (53%) 4 (50%) 2 (25%) 0.440
HbA1ca 7.9 ± 1.2 9.1 ± 1.5 8.2 ± 1.5 0.295
Phakia, pseudophakic (n) 3 (18%) 2 (25%) 1 (14%) 0.862
IOP (mmHg) 16.9 ± 2.4 15.8 ± 3.1 16.6 ± 2.6 0.600
BCVA (letters) 60.1 ± 14.0 62.9 ± 6.7 58.5 ± 12.7 0.771
CMT (μm)b 436 ± 146 443 ± 132 468 ± 22 0.916
IVTA = intravitreal triamcinolone; IOP = intraocular pressure; BCVA = best-corrected visual acuity; CMT = central macular thickness.
Values are mean ± standard deviation or median with interquartile range shown in box brackets.
an = 13, 4 and 7 for IOP rise <5 mmHg, 5-9 mmHg and ≥10 mmHg, respectively.
bn = 12, 5 and 4 for IOP rise <5 mmHg, 5-9 mmHg and ≥10 mmHg, respectively.
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mechanism to their formation, possibly through genetic
polymorphisms of the common steroid receptor in the tra-
becular meshwork and lens epithelium [15,20,21,30].
We conducted the present analysis to see whether there
was a similar correlation between IOP rise and visual
outcomes after intraocular steroid therapy. Our results
suggest that this is the case and that there may be a
common mechanism for IOP rise and vision improve-
ment. The correlation found in this analysis was not as
strong as that between IOP rise and cataract formation
[15]. This may be due to the small numbers available
for analysis. Despite this, there was a statistically signifi-
cant trend for eyes that had greater IOP rise to have
good visual outcomes and the study that the data is de-
rived from is of very high quality. The fact that the as-
sociation between IOP rise and VA improvement could
only be established for the 6 month VA outcomes may
be related to the fact that in DMO, VA improvements
occur slowly, especially in the patient group chosen for
this study – patients with recalcitrant DMO.
The major weakness of this retrospective analysis is
the relatively small number of patients available. In the-
ory, this would result in missing weak relationships. Our
findings should be viewed positively in light number of
patients analysed. The classifications of IOP rise we used
were not prospectively defined. Analyses based on these
are potentially subject to selection bias. None of the
measured baseline characteristics were found to be sta-
tistically significantly different between the groups. We
cannot be certain that unmeasured baseline characteris-
tic influenced our results.
As well as potentially adding to our knowledge of the
mechanisms of IVTA on macular oedema, this analysis
has clinical implications. It seems that those eyes that
have a high degree of IOP rise are more likely to have
very good visual outcomes 6 months after treatment,
with a mean improvement of 11.7 letters on an ETDRS
scale found in our subjects. Concurrently, these eyes are
at greater risk of developing posterior subcapsular cata-
ract [15]. This adds further complexity to the harm/
benefit analysis the clinician must make in deciding
whether to treat.
Conclusions
This analysis has revealed a positive relationship be-
tween the intraocular pressure rise and visual improve-
ment following IVTA treatment for DMO, at least in
the short term. This suggests that there may be a com-
mon mechanism to the development of these outcomes,
which is yet to be elucidated. These eyes are concur-
rently at higher risk of developing posterior subcapsular
cataract.
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Table 2 Vision improvement in eyes treated with IVTA stratified with respect to change in IOP from baseline
IOP change < 5 mmHg rise IOP rise 5–9 mmHg IOP rise ≥ 10 mmHg
P value
(n = 17) (n = 8) (n = 8)
1 month
Gain in BCVA≥ 5 letters 8 (47%) 2 (25%) 7 (88%) 0.044
Mean gain in visual acuity (letters) 4.0 [−0.5 to 6.0] 3.0 [0.0 to 6.3] 6.5 [5.3 to 12.0] 0.058
6 months
Gain in BCVA≥ 5 lettersa 9 (56%) 3 (43%) 5 (71%) 0.561
Mean gain in visual acuity (letters)a 4.8 ± 6.5 1.4 ± 7.4 11.7 ± 9.7 0.045
IVTA = intravitreal triamcinolone; IOP = intraocular pressure.
Values are mean ± standard deviation or median with interquartile range shown in box brackets.
an = 16, 7 and 7 for IOP rise <5 mmHg, 5-9 mmHg and ≥10 mmHg, respectively.
Table 3 Predicting IOP rise of 10 or more mmHG
Predictor Odds ratio 95% confidence
interval
P value
1 Month
Baseline age 1.00 0.91 – 1.10 0.972
Gender 2.61 0.39 – 17.62 0.325
Baseline phakia 1.32 0.10 – 17.05 0.831
Mean gain in visual acuity at
1 month (letters)
1.13 0.96 – 1.33 0.149
6 months
Baseline age 0.99 0.87 – 1.14 0.894
Gender 3.91 0.39 – 39.58 0.248
Baseline phakia 7.94 0.14 – 457.82 0.316
Mean gain in visual acuity at
6 months (letters)
1.22 1.01 – 1.48 0.039
IVTA = intravitreal triamcinolone; IOP = intraocular pressure; BCVA = best
corrected visual acuity.
Binary logistic regression analyses.
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